Expression of several other genes upregulated by ruxolitinib such as Csf2, Cx3cl1, Cx3cr1, Has1, and Ccl22 in myeloid cell populations is known to be associated with tumor progression, myeloid cell accumulation, and tumor progression51–56,76,77. Here, CSF2 is linked to neoplasm.